CORONA Remedies Share price

Our Company was originally incorporated as ‘CORONA Remedies Private Limited’ a private limited company under the Companies Act 1956 pursuant to a certificate of incorporation dated August 27 2004 issued by the Assistant Registrar of Companies Gujarat at Dadra and Nagar Haveli. Thereafter our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24 2024 and consequently the name of our Company was changed to ‘CORONA Remedies Limited’. A fresh certificate of incorporation upon conversion of our Company to a public limited company was issued by the Registrar of Companies Central Processing Centre Manesar Haryana on December 16 2024.Major events and milestones:2004- Launch of first division later named as ‘Pioneer’ division in 20102005- Launch of division (multispeciality): Xemx2007- Commencement of production at the first manufacturing plant at Solan Himachal Pradesh2008- Launch of division (gynaecology): Aarush2013- Launch of division (cardioloy): Wellness2016- Purchased the trademarks “Stelbid” and “Vitneurin” from Glaxo Group Limited- Purchased the trademarks "Dilo DX" and "Dilo-BM" from GlaxoSmithKline Pharmaceuticals Limited2018- Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis- Acquired the trademarks “Obimet” “Obimet-GX” “Obimet SR” “Obimet-V” “Triobimet” and “Thyrocab” (within India) from Abbott India Limited2020- Entered into a strategic alliance with La Chandra Pharmalab Private Limited2021- Commencement of production at the manufacturing plant at Ahmedabad Gujarat2022- Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris2023- Launch of division (urology): Blaze- Purchased the trademark “Myoril” (in India) from Sanofi Healthcare India Private Limited- Received EU GMP accreditation for the manufacturing plant at Ahmedabad Gujarat